Preclinical studies and preliminary clinical observations suggest combined neutralization of PD-L1 and TGF-β effects within the tumor microenvironment (TME) is promising, including after administration of tumor-targeted vaccine. LVGN1673 is an promising bifunctional fusion protein composed of a human IgG1 monoclonal antibody against PD-L1 fused with 2 extracellular domains of transforming growth factor beta (TGFβ) receptor to function as a TGF-β “trap”. Preclinical studies have shown that LVGN1673 is capable of blocking PD-L1 interactions and sequestering TGFβ1/2/3. Moreover, the potency and magnitude of antitumor responses in murine models appear to be greater with LVGN1673 treatment than with anti-PD-L1 or anti-TGFβ monotherapy.
We are preparing GMP-manufacture in our CMC site in Suzhou. We plan to apply IND in China and the USA in Q2 of 2021.
If you as a patient or caregiver wish to participate in this study, please contact us at the following address: email@example.com or send us a message